Incannex Healthcare (IXHL) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 70 252 sessions, November 10, 2025 to November 10, 2026
- Largest daily move
- -48.4% close of March 12, 2026
- 1-year change
- -81.5% closing prices, November 10, 2025 to November 10, 2026
- 1-month change
- -35.2% closing prices, October 9, 2026 to November 10, 2026
Company Description
Incannex Healthcare Inc. develops clinical-stage biopharmaceutical programs based on combination therapies and regulated botanical wellness medicine. The company’s common stock trades on Nasdaq under the symbol IXHL. Its business is centered on research and development programs for high-impact medical conditions, with company disclosures emphasizing investigational therapies for obstructive sleep apnea and generalized anxiety disorder.
The company’s lead disclosed program is IHL-42X, an investigational oral fixed-dose combination of dronabinol and acetazolamide designed for the treatment of obstructive sleep apnea. Incannex has described IHL-42X as a therapy intended to target underlying mechanisms of obstructive sleep apnea through the combined activity of its two active pharmaceutical ingredients. The program has been reported with Phase 2 clinical results, and the U.S. Food and Drug Administration has granted Fast Track Designation for IHL-42X.
Incannex also develops PSX-001, an oral fixed-dose synthetic botanical research compound formulation in development for generalized anxiety disorder. The company has reported completed Phase 2 clinical work for PSX-001 and positions the program within its broader development focus on novel therapies for serious mental-health conditions.
Incannex manages its business as one reportable and operating segment focused on research and development involving regulated botanical wellness medicine and therapies. Earlier company materials also describe an Australian license to import, export and distribute medicinal cannabis products, as well as a launched line of cannabinoid products. The company’s current public communications emphasize clinical development, regulatory interaction, capital structure, Nasdaq listing status and financing activities related to its investigational pipeline.
Corporate filings identify Incannex Healthcare Inc. as an emerging growth company and list its common stock as registered on The Nasdaq Stock Market LLC. The company has also disclosed capital-structure actions, including a completed 1-for-30 reverse stock split of its common stock and Nasdaq minimum bid price compliance matters. Its principal office is listed in Melbourne, Australia.
Stock Performance
Incannex Healthcare (IXHL) closed at $2.01 on November 10, 2026. Over the past 12 months, the price has lost 81.5%.
IXHL Metrics & Rankings
Price returns through November 10, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Incannex Healthcare has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include clinical trial. View all IXHL news →
SEC Filings
Incannex Healthcare has filed 10 recent SEC filings, including 6 Form 8-K, 1 Form ARS, 1 Form DEF 14A, 1 Form 10-K. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all IXHL SEC filings →
Financial Highlights
Incannex Healthcare reported operating income of -$23.0M in FY2026, and net income was -$19.3M. Diluted earnings per share stood at -$1.66. The company generated -$12.9M in operating cash flow. The current ratio was 48.81, measuring current assets divided by current liabilities.
Upcoming Events
Additional R&D Funding
DReAMzz study completion
IHL-42X patent expiry
IHL-42X patent expiry
Incannex Healthcare has 4 upcoming scheduled events. The next event, "Additional R&D Funding", is expected in 2027. 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the IXHL stock price.
Short Interest History
Short interest in Incannex Healthcare (IXHL) currently stands at 411.6 thousand shares, down 9.8% from the previous reporting period, representing 3.6% of the float. Since the latest stock split, short interest has decreased by 67.5%, measured from March 2026.
Days to Cover History
Days to cover for Incannex Healthcare (IXHL) currently stands at 6.6 days, up 69.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 246.3%. Across the settlements charted above, it has ranged from 1.0 to 10.0 days.
IXHL Company Profile & Sector Positioning
Incannex Healthcare (IXHL) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing IXHL often look at related companies in the same sector, including Shuttle Pharmaceuticals Holdings, Inc. (SHPH), SCYNEXIS, Inc. (SCYX), Rockwell Medical, Inc. (RMTI), China Pharma Holdings, Inc. (CPHI), and AYTU BioPharma, Inc. (AYTU). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate IXHL's relative position within its industry.